TGFB1 and non-small cell lung carcinoma: Using continuous TGF-β treatment to promote EMT, we experimentally induced EMT in the HCC827 EGFR mutant NSCLC cell line, with previously established sensitivity to the EGFR TKI erlotinib [17].